Covered recipient · General Payments record
TERESA KAY JOHNSON
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,835.50
- Reported across 166 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $324.49 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $122.97 | 6 |
| Novo Nordisk AS | $55.95 | 3 |
| Mylan Specialty L.P. | $52.25 | 3 |
| Astellas Pharma US Inc | $30.84 | 1 |
| GlaxoSmithKline, LLC. | $18.44 | 1 |
| Amgen Inc. | $16.13 | 1 |
| Exact Sciences Corporation | $14.20 | 1 |
| PFIZER INC. | $13.71 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.09 | 03/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104004243 | CMS |
| ABBVIE INC. | $14.77 | 03/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104004245 | CMS |
| ABBVIE INC. | $22.51 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104004247 | CMS |
| ABBVIE INC. | $29.21 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104004249 | CMS |
| ABBVIE INC. | $26.63 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104004251 | CMS |
| ABBVIE INC. | $16.76 | 12/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104004253 | CMS |
| Amgen Inc. | $16.13 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115770060 | CMS |
| Astellas Pharma US Inc | $30.84 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139403635 | CMS |
| Exact Sciences Corporation | $14.20 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114486746 | CMS |
| GlaxoSmithKline, LLC. | $18.44 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116531850 | CMS |
| Mylan Specialty L.P. | $16.39 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147327194 | CMS |
| Mylan Specialty L.P. | $16.68 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147284316 | CMS |
| Mylan Specialty L.P. | $19.18 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147346386 | CMS |
| Novo Nordisk Inc | $14.71 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097123294 | CMS |
| Novo Nordisk Inc | $21.69 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096724701 | CMS |
| Novo Nordisk Inc | $19.55 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096627921 | CMS |
| PFIZER INC. | $13.71 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131496204 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.